Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD

BACKGROUND: Formoterol fumarate inhalation solution (FFIS; Perforomist(®)) is a long-acting β(2)-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Chron Obstruct Pulmon Dis
Главные авторы: Hanania, Nicola A, Sethi, Sanjay, Koltun, Arkady, Ward, Jonathan K, Spanton, Jacqui, Ng, Dik
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2018
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6311322/
https://ncbi.nlm.nih.gov/pubmed/30643398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S173595
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы